CIK 0001484565
SLNO SOLENO THERAPEUTICS INC
Insider trading from SEC Form 4. Last filing Dec 17, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
8
with a Form 4 at this company
Signals
Open-market buys and sells at SOLENO THERAPEUTICS INC, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 14Weak | Patricia C Hirano SEE REMARKS sell | $317k 3,830 shares | -22% | - | |
| 0Weak | Patricia C Hirano SEE REMARKS sell | $22k 266 shares | -2% | - | |
| 28Weak | Patricia C Hirano SEE REMARKS sell | $265k 3,782 shares | -12% | - | |
| 70Notable | Bhatnagar Anish CHIEF EXECUTIVE OFFICER sell | $47M 699,095 shares | -93% | - | |
| 40Moderate | Patricia C Hirano SEE REMARKS sell | $11M 156,315 shares | -139% | - | |
| 50Moderate | Michael F. Huang Sr. VP of Clinical Development sell | $1.0M 14,583 shares | -35% | - | |
| 58Moderate | Bhatnagar Anish CHIEF EXECUTIVE OFFICER sell | $966k 21,091 shares | -3% | - | |
| 34Weak | Patricia C Hirano SEE REMARKS sell | $139k 3,030 shares | -3% | - |
Transactions
The last 89 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 15, 2025 | Bhatnagar Anish CHIEF EXECUTIVE OFFICER | FTax withholding Common Stock | -7,620 | $49.95 | $381k | 569,456 | Dec 17, 2025 |
| Dec 15, 2025 | Bhatnagar Anish CHIEF EXECUTIVE OFFICER | GGift Common Stock | -100,000 | $0.00 | $0 | 469,456 | Dec 17, 2025 |
| Jul 1, 2025 | Patricia C Hirano SEE REMARKS | SOpen-market sale Common Stock10b5-1 | -3,830 | $82.76 | $317k | 13,206 | Jul 3, 2025 |
| Jun 24, 2025 | Patricia C Hirano SEE REMARKS | MOption exercise Common Stock10b5-1 | +266 | $44.25 | $12k | 17,302 | Jun 26, 2025 |
| Jun 24, 2025 | Patricia C Hirano SEE REMARKS | SOpen-market sale Common Stock10b5-1 | -266 | $84.25 | $22k | 17,036 | Jun 26, 2025 |
| Jun 24, 2025 | Patricia C Hirano SEE REMARKS | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -266 | $0.00 | $0 | 0 | Jun 26, 2025 |
| Jun 5, 2025 | Birgitte Volck director | AGrant or award Common Stock | +3,991 | $0.00 | $0 | 17,536 | Jun 9, 2025 |
| Jun 5, 2025 | Andrew Sinclair director | AGrant or award Common Stock | +3,991 | $0.00 | $0 | 10,491 | Jun 9, 2025 |
| Jun 5, 2025 | Matthew Pauls director | AGrant or award Common Stock | +3,991 | $0.00 | $0 | 10,491 | Jun 9, 2025 |
| Jun 5, 2025 | William G Harris director | AGrant or award Common Stock | +3,991 | $0.00 | $0 | 19,392 | Jun 9, 2025 |
| Jun 5, 2025 | Dawn Carter Bir director | AGrant or award Common Stock | +3,991 | $0.00 | $0 | 16,991 | Jun 9, 2025 |
| Apr 1, 2025 | Patricia C Hirano SEE REMARKS | SOpen-market sale Common Stock10b5-1 | -3,782 | $70.11 | $265k | 27,036 | Apr 2, 2025 |
| Mar 27, 2025 | Michael F. Huang Sr. VP of Clinical Development | SOpen-market sale Common Stock | -371 | $65.97 | $24k | 41,029 | Mar 31, 2025 |
| Mar 27, 2025 | Patricia C Hirano SEE REMARKS | SOpen-market sale Common Stock10b5-1 | -1,418 | $65.97 | $94k | 110,884 | Mar 31, 2025 |
| Mar 27, 2025 | Bhatnagar Anish CHIEF EXECUTIVE OFFICER | SOpen-market sale Common Stock | -14,183 | $65.97 | $936k | 738,179 | Mar 31, 2025 |
| Mar 27, 2025 | Michael F. Huang Sr. VP of Clinical Development | SOpen-market sale Common Stock | -604 | $66.79 | $40k | 40,425 | Mar 31, 2025 |
| Mar 27, 2025 | Patricia C Hirano SEE REMARKS | SOpen-market sale Common Stock10b5-1 | -2,310 | $66.79 | $154k | 108,574 | Mar 31, 2025 |
| Mar 27, 2025 | Bhatnagar Anish CHIEF EXECUTIVE OFFICER | SOpen-market sale Common Stock | -23,095 | $66.79 | $1.5M | 715,084 | Mar 31, 2025 |
| Mar 27, 2025 | Patricia C Hirano SEE REMARKS | SOpen-market sale Common Stock10b5-1 | -4,199 | $67.70 | $284k | 104,375 | Mar 31, 2025 |
| Mar 27, 2025 | Michael F. Huang Sr. VP of Clinical Development | SOpen-market sale Common Stock | -1,098 | $67.70 | $74k | 39,327 | Mar 31, 2025 |
| Mar 27, 2025 | Bhatnagar Anish CHIEF EXECUTIVE OFFICER | SOpen-market sale Common Stock | -41,989 | $67.70 | $2.8M | 673,095 | Mar 31, 2025 |
| Mar 27, 2025 | Bhatnagar Anish CHIEF EXECUTIVE OFFICER | SOpen-market sale Common Stock | -55,234 | $68.79 | $3.8M | 617,861 | Mar 31, 2025 |
| Mar 27, 2025 | Patricia C Hirano SEE REMARKS | SOpen-market sale Common Stock10b5-1 | -5,524 | $68.79 | $380k | 98,851 | Mar 31, 2025 |
| Mar 27, 2025 | Michael F. Huang Sr. VP of Clinical Development | SOpen-market sale Common Stock | -1,444 | $68.79 | $99k | 37,883 | Mar 31, 2025 |
| Mar 27, 2025 | Bhatnagar Anish CHIEF EXECUTIVE OFFICER | SOpen-market sale Common Stock | -31,980 | $69.84 | $2.2M | 585,881 | Mar 31, 2025 |
| Mar 27, 2025 | Patricia C Hirano SEE REMARKS | SOpen-market sale Common Stock10b5-1 | -3,198 | $69.84 | $223k | 95,653 | Mar 31, 2025 |
| Mar 27, 2025 | Michael F. Huang Sr. VP of Clinical Development | SOpen-market sale Common Stock | -836 | $69.84 | $58k | 37,047 | Mar 31, 2025 |
| Mar 27, 2025 | Patricia C Hirano SEE REMARKS | SOpen-market sale Common Stock10b5-1 | -329 | $70.73 | $23k | 95,324 | Mar 31, 2025 |
| Mar 27, 2025 | Michael F. Huang Sr. VP of Clinical Development | SOpen-market sale Common Stock | -86 | $70.73 | $6,083 | 36,961 | Mar 31, 2025 |
| Mar 27, 2025 | Bhatnagar Anish CHIEF EXECUTIVE OFFICER | SOpen-market sale Common Stock | -3,291 | $70.73 | $233k | 582,590 | Mar 31, 2025 |
| Mar 27, 2025 | Michael F. Huang Sr. VP of Clinical Development | SOpen-market sale Common Stock | -125 | $71.74 | $8,968 | 36,836 | Mar 31, 2025 |
| Mar 27, 2025 | Bhatnagar Anish CHIEF EXECUTIVE OFFICER | SOpen-market sale Common Stock | -4,782 | $71.74 | $343k | 577,808 | Mar 31, 2025 |
| Mar 27, 2025 | Patricia C Hirano SEE REMARKS | SOpen-market sale Common Stock10b5-1 | -478 | $71.74 | $34k | 94,846 | Mar 31, 2025 |
| Mar 27, 2025 | Michael F. Huang Sr. VP of Clinical Development | SOpen-market sale Common Stock | -19 | $72.64 | $1,380 | 36,817 | Mar 31, 2025 |
| Mar 27, 2025 | Bhatnagar Anish CHIEF EXECUTIVE OFFICER | SOpen-market sale Common Stock | -732 | $72.64 | $53k | 577,076 | Mar 31, 2025 |
| Mar 27, 2025 | Patricia C Hirano SEE REMARKS | SOpen-market sale Common Stock10b5-1 | -73 | $72.64 | $5,303 | 94,773 | Mar 31, 2025 |
| Mar 27, 2025 | Michael F. Huang Sr. VP of Clinical Development | MOption exercise Common Stock | +10,000 | $21.93 | $219k | 46,817 | Mar 31, 2025 |
| Mar 27, 2025 | Bhatnagar Anish CHIEF EXECUTIVE OFFICER | MOption exercise Common Stock | +26,606 | $24.00 | $639k | 603,682 | Mar 31, 2025 |
| Mar 27, 2025 | Patricia C Hirano SEE REMARKS | MOption exercise Common Stock10b5-1 | +6,000 | $24.00 | $144k | 100,773 | Mar 31, 2025 |
| Mar 27, 2025 | Michael F. Huang Sr. VP of Clinical Development | SOpen-market sale Common Stock | -10,000 | $70.03 | $700k | 36,817 | Mar 31, 2025 |
| Mar 27, 2025 | Bhatnagar Anish CHIEF EXECUTIVE OFFICER | MOption exercise Common Stock | +16,666 | $25.05 | $417k | 620,348 | Mar 31, 2025 |
| Mar 27, 2025 | Patricia C Hirano SEE REMARKS | MOption exercise Common Stock10b5-1 | +4,400 | $25.05 | $110k | 105,173 | Mar 31, 2025 |
| Mar 27, 2025 | Michael F. Huang Sr. VP of Clinical Development | MOption exercise Employee stock option (right to buy)derivative | -10,000 | $0.00 | $0 | 110,000 | Mar 31, 2025 |
| Mar 27, 2025 | Patricia C Hirano SEE REMARKS | MOption exercise Common Stock10b5-1 | +4,888 | $5.10 | $25k | 110,061 | Mar 31, 2025 |
| Mar 27, 2025 | Bhatnagar Anish CHIEF EXECUTIVE OFFICER | MOption exercise Common Stock | +105,000 | $33.60 | $3.5M | 725,348 | Mar 31, 2025 |
| Mar 27, 2025 | Patricia C Hirano SEE REMARKS | MOption exercise Common Stock10b5-1 | +13,333 | $2.60 | $35k | 123,394 | Mar 31, 2025 |
| Mar 27, 2025 | Bhatnagar Anish CHIEF EXECUTIVE OFFICER | MOption exercise Common Stock | +32,193 | $5.10 | $164k | 757,541 | Mar 31, 2025 |
| Mar 27, 2025 | Patricia C Hirano SEE REMARKS | MOption exercise Common Stock10b5-1 | +8,333 | $2.41 | $20k | 131,727 | Mar 31, 2025 |
| Mar 27, 2025 | Bhatnagar Anish CHIEF EXECUTIVE OFFICER | MOption exercise Common Stock | +62,291 | $2.41 | $150k | 819,832 | Mar 31, 2025 |
| Mar 27, 2025 | Bhatnagar Anish CHIEF EXECUTIVE OFFICER | MOption exercise Common Stock | +281,053 | $5.25 | $1.5M | 1,100,885 | Mar 31, 2025 |
| Mar 27, 2025 | Patricia C Hirano SEE REMARKS | MOption exercise Common Stock10b5-1 | +35,186 | $5.25 | $185k | 166,913 | Mar 31, 2025 |
| Mar 27, 2025 | Bhatnagar Anish CHIEF EXECUTIVE OFFICER | SOpen-market sale Common Stock | -106,471 | $65.81 | $7.0M | 994,414 | Mar 31, 2025 |
| Mar 27, 2025 | Patricia C Hirano SEE REMARKS | SOpen-market sale Common Stock10b5-1 | -46,214 | $66.39 | $3.1M | 120,699 | Mar 31, 2025 |
| Mar 27, 2025 | Patricia C Hirano SEE REMARKS | SOpen-market sale Common Stock10b5-1 | -24,776 | $67.47 | $1.7M | 95,923 | Mar 31, 2025 |
| Mar 27, 2025 | Bhatnagar Anish CHIEF EXECUTIVE OFFICER | SOpen-market sale Common Stock | -209,689 | $66.33 | $14M | 784,725 | Mar 31, 2025 |
| Mar 27, 2025 | Patricia C Hirano SEE REMARKS | SOpen-market sale Common Stock10b5-1 | -24,989 | $70.18 | $1.8M | 70,934 | Mar 31, 2025 |
| Mar 27, 2025 | Bhatnagar Anish CHIEF EXECUTIVE OFFICER | SOpen-market sale Common Stock | -8,423 | $67.37 | $567k | 776,302 | Mar 31, 2025 |
| Mar 27, 2025 | Patricia C Hirano SEE REMARKS | SOpen-market sale Common Stock10b5-1 | -15,145 | $72.50 | $1.1M | 55,789 | Mar 31, 2025 |
| Mar 27, 2025 | Bhatnagar Anish CHIEF EXECUTIVE OFFICER | SOpen-market sale Common Stock | -199,226 | $69.30 | $14M | 577,076 | Mar 31, 2025 |
| Mar 28, 2025 | Patricia C Hirano SEE REMARKS | MOption exercise Common Stock10b5-1 | +2,691 | $33.60 | $90k | 58,480 | Mar 31, 2025 |
| Mar 27, 2025 | Bhatnagar Anish CHIEF EXECUTIVE OFFICER | MOption exercise Employee stock option (right to buy)derivative | -26,606 | $0.00 | $0 | 60 | Mar 31, 2025 |
| Mar 28, 2025 | Patricia C Hirano SEE REMARKS | SOpen-market sale Common Stock10b5-1 | -3,394 | $67.46 | $229k | 55,086 | Mar 31, 2025 |
| Mar 27, 2025 | Bhatnagar Anish CHIEF EXECUTIVE OFFICER | MOption exercise Employee stock option (right to buy)derivative | -16,666 | $0.00 | $0 | 0 | Mar 31, 2025 |
| Mar 27, 2025 | Bhatnagar Anish CHIEF EXECUTIVE OFFICER | MOption exercise Employee stock option (right to buy)derivative | -105,000 | $0.00 | $0 | 35,000 | Mar 31, 2025 |
| Mar 28, 2025 | Patricia C Hirano SEE REMARKS | SOpen-market sale Common Stock10b5-1 | -12,324 | $68.92 | $849k | 42,762 | Mar 31, 2025 |
| Mar 27, 2025 | Bhatnagar Anish CHIEF EXECUTIVE OFFICER | MOption exercise Employee stock option (right to buy)derivative | -32,193 | $0.00 | $0 | 8,473 | Mar 31, 2025 |
| Mar 28, 2025 | Patricia C Hirano SEE REMARKS | SOpen-market sale Common Stock10b5-1 | -9,253 | $69.52 | $643k | 33,509 | Mar 31, 2025 |
| Mar 28, 2025 | Patricia C Hirano SEE REMARKS | SOpen-market sale Common Stock10b5-1 | -2,691 | $73.60 | $198k | 30,818 | Mar 31, 2025 |
| Mar 27, 2025 | Bhatnagar Anish CHIEF EXECUTIVE OFFICER | MOption exercise Employee stock option (right to buy)derivative | -62,291 | $0.00 | $0 | 52,709 | Mar 31, 2025 |
| Mar 27, 2025 | Patricia C Hirano SEE REMARKS | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -6,000 | $0.00 | $0 | 0 | Mar 31, 2025 |
| Mar 27, 2025 | Bhatnagar Anish CHIEF EXECUTIVE OFFICER | MOption exercise Employee stock option (right to buy)derivative | -281,053 | $0.00 | $0 | 200,753 | Mar 31, 2025 |
| Mar 27, 2025 | Patricia C Hirano SEE REMARKS | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -4,400 | $0.00 | $0 | 0 | Mar 31, 2025 |
| Mar 27, 2025 | Patricia C Hirano SEE REMARKS | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -4,888 | $0.00 | $0 | 2,445 | Mar 31, 2025 |
| Mar 27, 2025 | Patricia C Hirano SEE REMARKS | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -13,333 | $0.00 | $0 | 0 | Mar 31, 2025 |
| Mar 27, 2025 | Patricia C Hirano SEE REMARKS | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -8,333 | $0.00 | $0 | 11,667 | Mar 31, 2025 |
| Mar 27, 2025 | Patricia C Hirano SEE REMARKS | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -35,186 | $0.00 | $0 | 49,262 | Mar 31, 2025 |
| Mar 28, 2025 | Patricia C Hirano SEE REMARKS | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -2,691 | $0.00 | $0 | 18,842 | Mar 31, 2025 |
| Jan 21, 2025 | Bhatnagar Anish CHIEF EXECUTIVE OFFICER | AGrant or award Common Stock | +53,900 | $0.00 | $0 | 752,362 | Jan 23, 2025 |
| Jan 21, 2025 | Patricia C Hirano SEE REMARKS | AGrant or award Common Stock | +6,400 | $0.00 | $0 | 112,302 | Jan 23, 2025 |
| Jan 21, 2025 | Michael F. Huang Sr. VP of Clinical Development | AGrant or award Common Stock | +6,400 | $0.00 | $0 | 41,400 | Jan 23, 2025 |
| Jan 21, 2025 | Bhatnagar Anish CHIEF EXECUTIVE OFFICER | AGrant or award Employee stock option (right to buy)derivative | +115,600 | $0.00 | $0 | 115,600 | Jan 23, 2025 |
| Jan 21, 2025 | Michael F. Huang Sr. VP of Clinical Development | AGrant or award Employee stock option (right to buy)derivative | +13,800 | $0.00 | $0 | 13,800 | Jan 23, 2025 |
| Jan 21, 2025 | Patricia C Hirano SEE REMARKS | AGrant or award Employee stock option (right to buy)derivative | +13,800 | $0.00 | $0 | 13,800 | Jan 23, 2025 |
| Jan 2, 2025 | Bhatnagar Anish CHIEF EXECUTIVE OFFICER | SOpen-market sale Common Stock | -10,077 | $45.37 | $457k | 709,476 | Jan 6, 2025 |
| Jan 2, 2025 | Patricia C Hirano SEE REMARKS | SOpen-market sale Common Stock | -1,447 | $45.37 | $66k | 107,485 | Jan 6, 2025 |
| Jan 2, 2025 | Bhatnagar Anish CHIEF EXECUTIVE OFFICER | SOpen-market sale Common Stock | -860 | $45.92 | $39k | 708,616 | Jan 6, 2025 |
| Jan 2, 2025 | Patricia C Hirano SEE REMARKS | SOpen-market sale Common Stock | -124 | $45.92 | $5,694 | 107,361 | Jan 6, 2025 |
| Jan 3, 2025 | Bhatnagar Anish CHIEF EXECUTIVE OFFICER | SOpen-market sale Common Stock | -10,154 | $46.18 | $469k | 698,462 | Jan 6, 2025 |
| Jan 3, 2025 | Patricia C Hirano SEE REMARKS | SOpen-market sale Common Stock | -1,459 | $46.18 | $67k | 105,902 | Jan 6, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Bhatnagar AnishCHIEF EXECUTIVE OFFICER
- Dawn Carter Birceo, president, officer, director
- William G Harrisdirector
- Patricia C HiranoSEE REMARKS
- Michael F. HuangSr. VP of Clinical Development
- Matthew Paulsceo, officer, director
- Andrew Sinclairdirector
- Birgitte Volckdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.